Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Guidant ACS Multi-Link RX Ultra

This article was originally published in The Gray Sheet

  • News

Executive Summary

Coronary stent system receives CE mark approval for use in saphenous vein grafts used in coronary artery bypass graft surgery, as well as in large native coronary vessels. The stent, which comes in 13, 18, 28 and 38 mm lengths and diameters from 3.5-5 mm, will be immediately available for sale in Europe. Also approved for the SVG indication are the ACS Multi-Link and ACS Multi-Link Duet stents

Table

View full table

Tags:
Latest Headlines

Discreet Gait Freezing Solution Brings Therapy With The Tap Of An Apple Watch

Shuren Says CDRH Is ‘Turning The Ship Around’ As Operations Return To Normal

EU: Good News For IVDs And For Future Transparency Of Medtech Compliance

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

See All
UsernamePublicRestriction

Register

MT011803

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By